Monitoring patients on linezolid
The CSM recommend that full blood counts are monitored weekly in patients who receive linezolid. The CSM also recommend close monitoring in patients who:
- receive more than 10-14 days of treatment with linezolid
- who receive linezolid treatment and have pre-existing myelosuppression
- have severe renal insufficiency
- are concomitantly being treated with other medication that may adversely affect haemoglobin levels, blood counts or platelet function
"If significant myelosuppression occurs during linezolid treatment, therapy should be stopped unless it is considered essential, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented (1)."
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page